United States Biotechnology & Medical Research

Cyclerion Therapeutics Inc (CYCN)

Track

Track

Cyclerion Therapeutics Inc. recently observed three proposed sales by Director Errol B. De Souza, totaling approximately $249,899. These transactions occurred following the company's August 2026 earnings report. The stock has experienced a 7.9% price change over the past ninety days, currently trading near its fifty-two-week low.
Ticker: CYCN Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Cyclerion Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
ERROL B DE SOUZA Director Non-Executive Director
Transaction date
Proposed sale
Price
18.88
Quantity 52,076
Value US$3,826,501
ERROL B DE SOUZA Director Non-Executive Director
Transaction date
Proposed sale
Price
372.09
Quantity 15,773
Value US$2,616,086
ERROL B DE SOUZA Director Non-Executive Director
Transaction date
Proposed sale
Price
490.77
Quantity 68,671
Value US$4,259,618
0.5
Slate Path Capital LP Large shareholder
Transaction date
Sale
Price
1.55
Quantity 357,880 -100.0%
Value US$555,108
1.4
MCGUIRE TERRANCE Non-Executive Director
Transaction date
Sale
Price
3.40
Quantity 8 -100.0%
Value US$27
2.6
Hecht Peter M Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.28
Quantity 823,170 +67.2%
Value US$2,699,998
1.4
MCGUIRE TERRANCE Non-Executive Director
Transaction date
Purchase
Price
3.12
Quantity 3,322 +15.4%
Value US$10,365
1.4
MCGUIRE TERRANCE Non-Executive Director
Transaction date
Purchase
Price
3.12
Quantity 92,831 +15.4%
Value US$289,633
2.6
Hecht Peter M Chief Executive Officer Executive Director
Transaction date
Purchase
Price
2.43
Quantity 302,000 +32.7%
Value US$733,860
Gjino Anjeza Chief Financial Officer Officer
Transaction date
Planned sale
Price
4.00
Quantity 1,824 -5.5%
Value US$7,296
Wright Christopher I Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.99
Quantity 2,637 -5.8%
Value US$10,522
2.0
Currie Mark G President and CSO Officer
Transaction date
Sale
Price
3.01
Quantity 20,107 -7.4%
Value US$60,522
4.2
Busch Andreas Chief Innovation Officer Officer
Transaction date
Planned purchase
Price
2.53
Quantity 125,000 +96.4%
Value US$316,250
0.5
Huyett William Chief Financial Officer Officer
Transaction date
Planned sale
Price
2.52
Quantity 3,827 -5.4%
Value US$9,644
0.5
Huyett William Chief Financial Officer Officer
Transaction date
Planned sale
Price
5.12
Quantity 3,559 -4.7%
Value US$18,222
2.0
Currie Mark G President Officer
Transaction date
Sale
Price
2.48
Quantity 25,000 -8.4%
Value US$62,000
Currie Mark G President Officer
Transaction date
Sale
Price
2.55
Quantity 25,000 -7.8%
Value US$63,750
Busch Andreas Chief Innovation Officer Officer
Transaction date
Purchase
Price
1.82
Quantity 125,000 +inf%
Value US$227,500
Huyett William Chief Financial Officer Officer
Transaction date
Planned sale
Price
2.05
Quantity 3,922 -5.0%
Value US$8,040
1.4
MCGUIRE TERRANCE
Transaction date
Purchase
Price
16.00
Quantity 21,635 +inf%
Value US$346,160
1.4
MCGUIRE TERRANCE
Transaction date
Purchase
Price
16.00
Quantity 604,482 +inf%
Value US$9,671,712
2.7
SCHULMAN AMY W
Transaction date
Purchase
Price
16.00
Quantity 21,635 +inf%
Value US$346,160
2.7
SCHULMAN AMY W
Transaction date
Purchase
Price
16.00
Quantity 604,482 +inf%
Value US$9,671,712
2.0
Currie Mark G President
Transaction date
Purchase
Price
14.81
Quantity 270,107 +523.0%
Value US$4,000,285
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-23 2026-09-23 PrS Proposed sale
ERROL B DE SOUZA

Director

Non-Executive Director
52,076
18.88
US$3,826,501 		52,076 18.88 US$3,826,501
2026-09-22 2026-09-22 PrS Proposed sale
ERROL B DE SOUZA

Director

Non-Executive Director
15,773
372.09
US$2,616,086 		15,773 372.09 US$2,616,086
2026-09-18 2026-09-18 PrS Proposed sale
ERROL B DE SOUZA

Director

Non-Executive Director
68,671
490.77
US$4,259,618 		68,671 490.77 US$4,259,618
2024-11-25 2024-11-21 S Sale
0.5
Slate Path Capital LP
Large shareholder
357,880 -100.0%
1.55
US$555,108 		357,880 -100.0% 1.55 US$555,108
2023-08-11 2023-08-09 S Sale
1.4
MCGUIRE TERRANCE
Non-Executive Director
8 -100.0%
3.40
US$27 		8 -100.0% 3.40 US$27
2021-06-07 2021-06-03 B Purchase
2.6
Hecht Peter M

Chief Executive Officer

Executive Director
823,170 +67.2%
3.28
US$2,699,998 		823,170 +67.2% 3.28 US$2,699,998
2021-06-07 2021-06-03 B Purchase
1.4
MCGUIRE TERRANCE
Non-Executive Director
3,322 +15.4%
3.12
US$10,365 		3,322 +15.4% 3.12 US$10,365
2021-06-07 2021-06-03 B Purchase
1.4
MCGUIRE TERRANCE
Non-Executive Director
92,831 +15.4%
3.12
US$289,633 		92,831 +15.4% 3.12 US$289,633
2021-05-10 2021-05-06 B Purchase
2.6
Hecht Peter M

Chief Executive Officer

Executive Director
302,000 +32.7%
2.43
US$733,860 		302,000 +32.7% 2.43 US$733,860
2021-03-01 2021-02-25 PlS Planned sale
Gjino Anjeza

Chief Financial Officer

Officer
1,824 -5.5%
4.00
US$7,296 		1,824 -5.5% 4.00 US$7,296
2021-03-01 2021-02-25 PlS Planned sale
Wright Christopher I

Chief Medical Officer

Officer
2,637 -5.8%
3.99
US$10,522 		2,637 -5.8% 3.99 US$10,522
2020-12-30 2020-12-28 S Sale
2.0
Currie Mark G

President and CSO

Officer
20,107 -7.4%
3.01
US$60,522 		20,107 -7.4% 3.01 US$60,522
2020-11-12 2020-11-09 PP Planned purchase
4.2
Busch Andreas

Chief Innovation Officer

Officer
125,000 +96.4%
2.53
US$316,250 		125,000 +96.4% 2.53 US$316,250
2020-11-10 2020-11-06 PlS Planned sale
0.5
Huyett William

Chief Financial Officer

Officer
3,827 -5.4%
2.52
US$9,644 		3,827 -5.4% 2.52 US$9,644
2020-02-25 2020-02-21 PlS Planned sale
0.5
Huyett William

Chief Financial Officer

Officer
3,559 -4.7%
5.12
US$18,222 		3,559 -4.7% 5.12 US$18,222
2019-12-31 2019-12-30 S Sale
2.0
Currie Mark G

President

Officer
25,000 -8.4%
2.48
US$62,000 		25,000 -8.4% 2.48 US$62,000
2019-12-31 2019-12-27 S Sale Currie Mark G

President

Officer
25,000 -7.8%
2.55
US$63,750 		25,000 -7.8% 2.55 US$63,750
2019-11-19 2019-11-15 B Purchase Busch Andreas

Chief Innovation Officer

Officer
125,000 +inf%
1.82
US$227,500 		125,000 +inf% 1.82 US$227,500
2019-11-12 2019-11-08 PlS Planned sale Huyett William

Chief Financial Officer

Officer
3,922 -5.0%
2.05
US$8,040 		3,922 -5.0% 2.05 US$8,040
2019-04-10 2019-04-08 B Purchase
1.4
MCGUIRE TERRANCE
21,635 +inf%
16.00
US$346,160 		21,635 +inf% 16.00 US$346,160
2019-04-10 2019-04-08 B Purchase
1.4
MCGUIRE TERRANCE
604,482 +inf%
16.00
US$9,671,712 		604,482 +inf% 16.00 US$9,671,712
2019-04-10 2019-04-08 B Purchase
2.7
SCHULMAN AMY W
21,635 +inf%
16.00
US$346,160 		21,635 +inf% 16.00 US$346,160
2019-04-10 2019-04-08 B Purchase
2.7
SCHULMAN AMY W
604,482 +inf%
16.00
US$9,671,712 		604,482 +inf% 16.00 US$9,671,712
2019-04-03 2019-04-02 B Purchase
2.0
Currie Mark G

President
270,107 +523.0%
14.81
US$4,000,285 		270,107 +523.0% 14.81 US$4,000,285
Explore more

More insider trading research around Cyclerion Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America